​

Beam Therapeutics (BEAM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BEAM Stock Forecast

Beam Therapeutics (BEAM) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $39.50, with a high of $57.00 and a low of $25.00. This represents a 132.35% increase from the last price of $17.00.

$15 $24 $33 $42 $51 $60 High: $57 Avg: $39.5 Low: $25 Last Closed Price: $17

BEAM Stock Rating

Beam Therapeutics stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (69.57%), 7 Hold (30.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 7 16 Strong Sell Sell Hold Buy Strong Buy

BEAM Price Target Upside V Benchmarks

TypeNameUpside
StockBeam Therapeutics132.35%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$25.00$45.40
Last Closing Price$17.00$17.00$17.00
Upside/Downside-47.06%167.06%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254103--17
Mar, 25386--17
Feb, 25376--16
Jan, 25388--19
Dec, 24378--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 03, 2025Scotiabank$25.00$25.10-0.40%47.06%
Jan 07, 2025William PickeringTudor Pickering$37.00$27.0836.63%117.65%
Nov 06, 2024Rick BienkowskiLeerink Partners$39.00$24.3460.23%129.41%
Nov 05, 2024Kostas BiliourisBMO Capital$57.00$24.34134.18%235.29%
Sep 11, 2024Benjamin BurnettStifel Nicolaus$69.00$23.34195.63%305.88%
Feb 01, 2023Cantor Fitzgerald$62.00$43.4542.69%264.71%
Dec 20, 2022Kostas BiliourisBMO Capital$66.00$41.5958.69%288.24%
Dec 13, 2022Citigroup$62.00$48.1928.66%264.71%
Apr 28, 2022Credit Suisse$62.00$39.8355.66%264.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 11, 2025ScotiabankSector PerformOutperformupgrade
Mar 03, 2025ScotiabankSector PerformSector Performhold
Jan 29, 2025Cantor FitzgeraldOverweightOverweightupgrade
Jan 07, 2025BernsteinOutperformupgrade
Jan 07, 2025BernsteinOutperformOutperformhold
Nov 06, 2024Leerink PartnersOutperformupgrade
Nov 05, 2024BMO CapitalOutperformOutperformhold
Sep 11, 2024H.C. WainwrightUnderperformUnderperformhold
Aug 22, 2024RBC CapitalSector PerformSector Performhold
Jul 23, 2024H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-10 $-8 $-6 $-4 $-2 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.49$-5.31$-3.76$-1.72$-4.58----
Avg Forecast$-2.92$-5.70$-4.73$-4.25$-4.70$-4.78$-4.79$-4.52$-3.27
High Forecast$-0.91$-1.79$-1.37$-3.80$-4.45$-3.88$-2.96$-3.07$-1.11
Low Forecast$-4.83$-9.45$-8.72$-4.54$-5.07$-5.42$-6.09$-6.46$-5.68
Surprise %88.01%-6.84%-20.51%-59.53%-2.55%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.00K$51.84M$60.92M$377.71M-----
Avg Forecast$10.00K$11.60M$54.19M$79.64M$52.13M$61.15M$51.80M$63.64M$223.37M
High Forecast$15.05K$17.46M$89.28M$97.34M$70.90M$81.53M$81.24M$63.68M$350.31M
Low Forecast$4.72K$5.47M$24.56M$70.49M$43.01M$32.61M$25.53M$63.61M$110.10M
Surprise %140.00%347.03%12.42%374.29%-----

Net Income Forecast

$-800M $-650M $-500M $-350M $-200M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-256.42M$-341.36M$-263.59M$-132.53M$-376.74M----
Avg Forecast$-225.06M$-631.79M$-272.02M$-132.53M$-367.10M$-410.03M$-442.92M$-465.37M$-251.93M
High Forecast$-70.58M$-505.43M$-217.61M$-106.02M$-343.10M$-298.99M$-228.60M$-236.78M$-85.85M
Low Forecast$-372.85M$-758.14M$-326.42M$-159.03M$-391.10M$-418.41M$-469.63M$-498.03M$-438.04M
Surprise %13.93%-45.97%-3.10%-2.63%----

BEAM Forecast FAQ

Is Beam Therapeutics stock a buy?

Beam Therapeutics stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Beam Therapeutics is a favorable investment for most analysts.

What is Beam Therapeutics's price target?

Beam Therapeutics's price target, set by 23 Wall Street analysts, averages $39.5 over the next 12 months. The price target range spans from $25 at the low end to $57 at the high end, suggesting a potential 132.35% change from the previous closing price of $17.

How does Beam Therapeutics stock forecast compare to its benchmarks?

Beam Therapeutics's stock forecast shows a 132.35% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Beam Therapeutics over the past three months?

  • April 2025: 23.53% Strong Buy, 58.82% Buy, 17.65% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 17.65% Strong Buy, 47.06% Buy, 35.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 18.75% Strong Buy, 43.75% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.

What is Beam Therapeutics’s EPS forecast?

Beam Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.78, marking a 4.37% increase from the reported $-4.58 in 2024. Estimates for the following years are $-4.79 in 2026, $-4.52 in 2027, and $-3.27 in 2028.

What is Beam Therapeutics’s revenue forecast?

Beam Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $61.15M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $51.8M, followed by $63.64M for 2027, and $223.37M for 2028.

What is Beam Therapeutics’s net income forecast?

Beam Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-410M, representing an 8.84% increase from the reported $-377M in 2024. Projections indicate $-443M in 2026, $-465M in 2027, and $-252M in 2028.